Bristol-Myers Squibb has agreed to buy the cancer specialist just two months after its series B round, in a deal that will involve $800m in cash upfront.

Alzheimer's drug developer Heptares has been acquired by pharmaceutical company Sosei, providing exits to corporate backers Novartis and Takeda.

Merganser Biotech, a company founded on UCLA tech, raises $28m series A.

Cambridge spin-out Cambridge Chocolate Technologies unveils chocolate with anti-ageing properties.

Merganser, which is developing treatments for haematological and iron overload diseases, has raised $28m in a Novartis-led round.

Molecular diagnostics company Lifecode has attracted funding from investors including Mayo Clinic and Mayo Ventures.

MedImmune-backed Inotek, which is working on treatments for glaucoma, priced its IPO at $6a share and is set to secure an additional $20m in convertible debt.